Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05761028 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of CM310 in Subjects With Moderate to Severe Asthma

StatusRecruiting
PhasePhase 2/3
Started2023-04-28
View on ClinicalTrials.gov ↗

Amendment history

2023-12-14
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2028-06→2032-05
Completion date2028-06→2032-05
Start dateestimated 2023-05→confirmed 2023-04-28
Study sitesdetails revised at 1 of 1 site
2023-02-27
Original filing
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week randomized treatment period, and a 4-week safety follow-up period.
Trial Details
NCT Number NCT05761028
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Moderate to Severe Asthma
Enrollment 600 participants
Start Date 2023-04-28
Primary Completion 2032-05 (estimated)
Study Completion 2032-05 (estimated)
Updated on ClinicalTrials.gov 2023-12-15